^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor) +
    AiRuiYi (fluzoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

    Excerpt:
    ...Progression Free Survival (PFS) in relapsed ovarian patients`Progression Free Survival (PFS) in BRCA1/2 mutated relapsed ovarian cancer patients.`...
    Trial ID:
    NCT05479487
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Med
    Title:

    A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

    Published date:
    09/29/2023
    Excerpt:
    Patients with gBRCAmut had higher ORR and longer median progression-free survival (PFS) than those with gBRCAwt, both in OC (ORR, 62.5% [5/8] vs 40.9% [9/22]; PFS, 9.4 vs 6.7 months) and TNBC (ORR, 66.7% [2/3] vs 15.8% [3/19]; PFS, 5.6 vs 2.8 months)….In summary, the combination of fuzuloparib and apatinib showed hematologic DLTs and acceptable safety in patients with recurrent OC and TNBC.
    DOI:
    https://doi.org/10.1186/s12916-023-03046-8
    Trial ID:
    NCT03075462